Showing results (141-150 of 174) with videos related to
Sort By:
Pageof 18
Plos Pathogens|December 5, 2012
Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesisJessica L Prince, Daniel T Claiborne, Jonathan M Carlson, et al.Vaccine|January 26, 2007
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicityBarry S Peters, Walter Jaoko, Eftyhia Vardas, et al.Journal of Virology|April 28, 2006
Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopesNilu Goonetilleke, Stephen Moore, Len Dally, et al.AIDS Research and Human Retroviruses|December 1, 2009
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteersVadakkuppatu Devasenapathi Ramanathan, Makesh Kumar, Jayashri Mahalingam, et al.Plos One|May 12, 2015
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African AdultsGloria Omosa-Manyonyi, Juliet Mpendo, Eugene Ruzagira, et al.Plos Pathogens|January 9, 2015
Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipientsLing Yue, Katja J Pfafferott, Joshua Baalwa, et al.AIDS Research and Human Retroviruses|November 25, 2010
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern AfricaMatt A Price, Carole L Wallis, Shabir Lakhi, et al.Frontiers in Immunology|March 10, 2017
A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization RegimesSarah Joseph, Killian Quinn, Aldona Greenwood, et al.Frontiers in Immunology|June 10, 2017
A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine RegimensSven Kratochvil, Paul F McKay, Jakub T Kopycinski, et al.Plos One|August 8, 2012
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adultsMichael C Keefer, Jill Gilmour, Peter Hayes, et al.Pageof 18